Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another CAR-T First: Yescarta Wins Lymphoma Funding In England

Executive Summary

Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.

You may also be interested in...



New Thinking Needed On Reimbursement Of Cell And Gene Therapies

One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.

UK: Funding For Second Kymriah Indication After Talks And Price Cut

UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.

CAR-T Funding: It's (Nearly) All About The Price In The UK

Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel